Kazuki Nozawa, MD· @kazuki_nozawa · X·· 2 days agoScore70
Body · original
TALENT trial
#ESMO26
Neoadjuvant T-DXd showed modest efficacy (pCR 3–9%), with limited benefit from additional therapy and potential safety concerns.
572 views · 8 likes · 3 reposts · 0 replies
Conference abstracts
LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.orgSource: Kazuki Nozawa, MD · x.com